100% Pharma Tariffs Hit September 29: Your Section 232 Survival Guide

On September 29, 2026, Section 232 tariffs of up to 100% expand to cover patented pharmaceuticals from virtually every company on the planet. If you import anything classified under Chapters 29 or 30, your cost structure is about to change dramatically — and a last-minute Federal Register notice just rewrote some of the exemption rules. Here's exactly what you need to know.

The pharmaceutical import landscape in the United States just underwent its most dramatic shift since the Smoot-Hawley era. When the clock strikes 12:01 a.m. Eastern on September 29, 2026, every company importing patented pharmaceuticals, active pharmaceutical ingredients (APIs), and key starting materials (KSMs) into the U.S. becomes subject to Section 232 tariffs — unless they qualify for one of several narrowly defined exemptions.

This isn't a surprise. Presidential Proclamation 11020, signed on April 2, 2026, laid out the framework months ago. Phase 1 hit 17 major pharmaceutical companies named in Annex III on July 31. But September 29 is Phase 2 — the moment thousands of smaller manufacturers, specialty drug makers, contract development organizations (CDMOs), and compounding pharmacies discover whether they're paying 100%, 15%, or nothing at all.

And on September 23 — just six days before the deadline — the Bureau of Industry and Security dropped a Federal Register notice (FR Doc. 2026-19498) that redefined specialty drug exemptions, created an entirely new HTS heading for clinical trial materials, and expanded the definition of generics. If you haven't read it yet, keep reading.

How We Got Here: Proclamation 11020 and the Section 232 Framework

On April 2, 2026, President Trump signed Proclamation 11020 under Section 232 of the Trade Expansion Act of 1962 (19 U.S.C. § 1862), imposing tariffs on pharmaceutical imports based on a national security finding that U.S. dependence on foreign-manufactured drugs and ingredients poses a strategic vulnerability.

The proclamation targets three categories of goods:

• Patented pharmaceutical products — finished dosage forms with active patents or market exclusivity
• Active Pharmaceutical Ingredients (APIs) — the chemical compounds that make drugs work
• Key Starting Materials (KSMs) — the precursor chemicals used to synthesize APIs

Generic pharmaceuticals, biosimilars, and their ingredients are currently exempt — though Commerce is required to review whether action on generics is warranted within one year of the proclamation.

The tariff is structured as a combined rate — not an add-on. Importers pay the higher of the applicable Section 232 rate or their Column 1 HTSUS rate, not both stacked together. And if a product qualifies under multiple Section 232 headings, the lowest applicable rate applies. That's a critical detail that could save you millions.

The Rate Structure: What You'll Actually Pay

Here's where it gets complicated — and where the money is. Proclamation 11020 established a tiered framework with mutually exclusive HTS headings under Chapter 99:

That 100% default isn't a typo. If your patented drug doesn't qualify for a country-specific rate, an onshoring plan, or an MFN deal, you're looking at a combined duty rate of 100% ad valorem. For a $50 million annual API import book, that's $50 million in duties — overnight.

Who's Already Paying: The Annex III Companies

Phase 1 hit on July 31, 2026, targeting 17 major pharmaceutical companies listed in Annex III of Proclamation 11020. These are the largest global pharma manufacturers — the companies with the scale and negotiating leverage the administration wanted to bring to the table first.

But here's what most people miss: many Annex III companies also appear in Annex II, meaning they've signed Most Favored Nation (MFN) pricing agreements with the administration. Those companies enter at 0% under 9903.04.65 through January 20, 2029. The 13 companies listed in Annex II effectively have a tariff holiday — as long as their pricing deal holds.

For everyone else, the 9903.04.61 heading provided a temporary 0% rate from July 31 through September 28, 2026. That grace period ends tomorrow.

What September 29 Changes for Everyone Else

Starting September 29, the 9903.04.61 zero-rate heading expires. Every company not in Annex II or Annex III now files under the rate that matches their situation:

1. No exemption? You're at 9903.04.60 — 100% combined duty
2. Importing from Japan, the EU, Korea, Switzerland, or Liechtenstein? File under 9903.04.62 — 15% combined
3. Importing from the UK? File under 9903.04.63 — 10% combined
4. Have an approved Commerce onshoring plan? File under 9903.04.64 — 20% combined, but that rate sunsets to 100% on April 2, 2030
5. Importing generics? File under 9903.04.67 — 0%
6. Importing for clinical trials or R&D? File under the brand-new 9903.04.70 — 0%

The reporting requirement isn't new. Since July 31, 2026, CBP has required all importers of goods classified under Chapters 29 and 30 to report an applicable Chapter 99 classification — even when the rate was zero. If you haven't been reporting, you're already behind. CBP issued CSMS #69395344 with detailed filing guidance.

The Last-Minute Curveball: BIS Notice 2026-19498

On September 23, 2026, the Bureau of Industry and Security published FR Doc. 2026-19498 (91 FR 60360), and it changed three things that matter enormously:

1. Specialty Drug Exemptions — Finally Defined

Proclamation 11020 promised a zero rate for "specialty pharmaceutical products," but left the definition to Commerce. The September 23 notice finally draws the line. These categories qualify for 0% under clause 3(d):

• Orphan drugs — all approved indications must be designated under the Orphan Drug Act (21 U.S.C. § 360aa)
• Nuclear medicines
• Plasma-derived therapies
• Fertility drugs
• Cell therapy products
• Gene therapy products
• Antibody drug conjugates (ADCs)
• CBRN medical countermeasures — chemical, biological, radiological, and nuclear threat treatments
• Animal health products (expanded in this notice)

The catch: these products must be either (a) products of one of 19 listed jurisdictions — including the EU, Japan, Korea, Switzerland, the UK, and India — or (b) approved by Commerce for an urgent U.S. health need, requested via email to BIS.

2. Clinical Trial Material Gets Its Own Heading

This is huge for CROs and sponsors. The notice created 9903.04.70 at a 0% rate for clinical trial material, research and development compounds, and other non-commercial pharmaceutical imports. It's effective for entries from September 29, 2026.

Clinical supply teams that previously shipped investigational product under ordinary entries now have a dedicated zero-rate heading — but you'll need protocol documentation or R&D records to support the classification.

3. Generic Definition Expanded

The notice expanded the generic exemption under 9903.04.67 to include unpatented animal health products, effective September 29. But here's the critical nuance: patent and exclusivity status must be confirmed per product. A patented version of the same molecule as a generic falls under the 100% default. You can't assume a drug is generic because a generic version exists — your specific import must be unpatented.

The Classification Trap: Why Patent Status Is Your New Gatekeeper

This is where importers are going to get burned. The entire Section 232 pharmaceutical framework pivots on a single question: is your product patented?

Generics at 0%. Patented drugs at up to 100%. The spread between those rates is the largest duty differential in the current HTSUS. And the determination isn't simple:

• A molecule can have both patented and unpatented versions — each classified differently
• Market exclusivity (FDA Orange Book listings) counts — it's not just about patent office records
• API sourcing matters: a generic finished dose form using a patented API may still be subject to the 100% rate on the ingredient
• Patent expiration dates create a moving target — products can shift from 100% to 0% mid-year

CBP will expect importers to maintain documentation supporting their patent-status classification. If you're filing under 9903.04.67 (generics, 0%), you'd better have the Orange Book data, patent search results, and supplier certifications to back it up.

Country of Origin: Where Your Drug Comes From Matters More Than Ever

The tiered rate structure creates massive duty arbitrage based on country of origin:

For patented APIs historically sourced from China — and there are many — the 100% rate creates an immediate incentive to shift to EU, UK, or Japanese suppliers. Expect the contract pharmaceutical manufacturing market in Ireland, Germany, and the UK to tighten significantly in Q4 2026.

But be careful: USMCA and other free trade agreements do not remove pharmaceutical Section 232 duties. CBP has confirmed that Section 232 rates apply in addition to any FTA or preference-program rate. Don't assume your USMCA certificate gets you out of this.

What to Do Before September 29

If you're reading this the day it was published, you have hours — not days. But even after September 29, these steps are critical:

1. Audit every Chapter 29 and 30 import line — Confirm which products are patented vs. generic. Check FDA Orange Book listings, patent databases, and supplier documentation. One wrong classification could mean 100% duty on a product that should enter at 0%.

2. Verify your Chapter 99 reporting — You should have been filing Chapter 99 headings since July 31. If you haven't, work with your broker immediately to correct prior entries via Post Summary Correction (PSC) before CBP flags them.

3. Check specialty drug eligibility — If you import orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell/gene therapies, ADCs, or CBRN countermeasures, determine whether your products qualify under the September 23 BIS notice. Confirm your source jurisdiction is among the 19 listed countries.

4. Reclassify clinical trial imports — If you're a CRO or sponsor importing investigational material, switch to the new 9903.04.70 heading effective September 29. Ensure you have protocol documentation and R&D records supporting non-commercial use.

5. Evaluate onshoring plans — The 20% rate under 9903.04.64 requires a Commerce-approved onshoring agreement. Applications go through BIS under the procedures published May 13, 2026 (92 FR 26989). The rate rises to 100% on April 2, 2030, so this is a medium-term play, not a permanent solution.

6. Model the supply chain math — For patented APIs from high-rate origins, run the numbers on switching to EU, UK, or Japanese suppliers. A 15% rate vs. 100% changes the entire make-vs-buy calculation.

What's Coming Next

The pharmaceutical Section 232 landscape isn't static. Watch for:

• Generic review — Commerce must report to the President within one year (by April 2027) on whether tariffs on generics are warranted. The current 0% rate for generics is not guaranteed to last.
• MFN deal expirations — Annex II companies' 0% rate expires January 20, 2029. Renegotiations will start well before then.
• Onshoring rate escalation — The 20% onshoring rate jumps to 100% on April 2, 2030. Companies banking on this pathway need to accelerate domestic manufacturing timelines.
• Additional specialty product designations — The Secretary of Commerce can identify additional specialty products for 0% treatment. Lobbying efforts are already underway for several therapeutic categories.
• Enforcement ramp-up — CBP is expected to increase scrutiny of patent-status claims, especially at the generic/patented boundary. Expect Requests for Information (CF-28s) and focused assessments targeting pharmaceutical entries.

The Biggest Tariff Shift Pharma Has Ever Seen

A 100% tariff on patented pharmaceuticals would have been unthinkable two years ago. Now it's the default rate for thousands of companies starting tomorrow. The exemptions are real — generics, specialty drugs, country-specific rates, MFN deals, onshoring plans — but they're narrow, documentation-heavy, and subject to change.

The importers who come through this cleanly will be the ones who treated classification as a strategic function, not an afterthought. Know your patent status. Know your country of origin. Know your HTS headings. And if you're still sorting it out, TariffLens can help you map every product to the right Section 232 classification before your next entry hits ACE.

This article is for informational purposes only and does not constitute legal, tax, or customs advice. Consult a licensed customs broker or trade attorney for guidance specific to your situation.